Biomaterials in cardiopulmonary bypass.
The improved utilization of biomaterials in cardiopulmonary bypass is dependent on polymer science and technology, procedures for blood compatibility assessment, optimization of biomaterial/antithrombotic agent combinations and the interpretation of clinical data.
Courtney
J M
JM
Bioengineering Unit, University of Strathclyde, Glasgow, UK.
Sundaram
S
S
Matata
B M
BM
Gaylor
J D
JD
D001672:Biocompatible Materials / Q000009:adverse effects*; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006355:Heart-Lung Machine; D006487:Hemostasis / Q000502:physiology; D006801:Humans; D013927:Thrombosis / Q000209:etiology
D001672:Biocompatible Materials; D005343:Fibrinolytic Agents